George Christoff

Prevention of Cardiovascular and Other Systemic Adverse Outcomes in Patients with Asthma Treated with Biologics

International Severe Asthma Registry (ISAR): 2017–2024 Status and Progress Update

Allergic Rhinitis and Its Impact on Asthma ( <scp>ARIA</scp> )‐ <scp>EAACI</scp> Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal Treatments

Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma ( <scp>ARIA</scp> )‐EAACI 2024–2025 Guidelines: From Evidence‐to‐Decision Frameworks to Digitalised Shared Decision‐Making Algorithms

Association between pre-biologic T2-biomarker combinations and response to biologics in patients with severe asthma

Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort

Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma Registry

Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma

Impact of Initiating Biologics in Patients With Severe Asthma on Long-Term Oral Corticosteroids or Frequent Rescue Steroids (GLITTER): Data From the International Severe Asthma Registry

Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

Different phenotypes of drug‐induced anaphylaxis—Data from the European Anaphylaxis Registry

Eosinophilic and Noneosinophilic Asthma

Defining a Severe Asthma Super-Responder: Findings from a Delphi Process

Wheat Anaphylaxis in Adults Differs from Reactions to Other Types of Food

Management of anaphylaxis due to COVID‐19 vaccines in the elderly

ARIA‐EAACI statement on asthma and COVID‐19 (June 2, 2020)

Phenotype and risk factors of venom-induced anaphylaxis: A case-control study of the European Anaphylaxis Registry

Risk Factors and Characteristics of Biphasic Anaphylaxis

International severe asthma registry (ISAR): protocol for a global registry

Anaphylaxis in Elderly Patients—Data From the European Anaphylaxis Registry

Secondary prevention measures in anaphylaxis patients: Data from the anaphylaxis registry

Factors increasing the risk for a severe reaction in anaphylaxis: An analysis of data from The European Anaphylaxis Registry

First European data from the network of severe allergic reactions (<scp>NORA</scp>)